Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA

BACKGROUND: Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung cancer (ALK(+) NSCLC), but clinical courses vary widely. Early identification and molecular characterisation of treatment failure have key importance for subsequent therapies. We performed copy number variation (...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:EBioMedicine
Autori principali: Dietz, Steffen, Christopoulos, Petros, Yuan, Zhao, Angeles, Arlou Kristina, Gu, Lisa, Volckmar, Anna-Lena, Ogrodnik, Simon J., Janke, Florian, Fratte, Chiara Dalle, Zemojtel, Tomasz, Schneider, Marc A., Kazdal, Daniel, Endris, Volker, Meister, Michael, Muley, Thomas, Cecchin, Erika, Reck, Martin, Schlesner, Matthias, Thomas, Michael, Stenzinger, Albrecht, Sültmann, Holger
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2020
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7670098/
https://ncbi.nlm.nih.gov/pubmed/33161228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.103103
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi